NCT05324995View on ClinicalTrials.gov

Peri-Articular-Multimodal Drug and Oral Celecoxib in Management of Postoperative Pain of Total Knee Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

March 1, 2022

Conditions
Postoperative PainTotal Knee Arthroplasty
Interventions
DRUG

Multimodal Drug

The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally

DRUG

epinephrine

The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary

DRUG

celecoxib

The third group administered celecoxib (200 mg) orally immediately before the surgery

Trial Locations (1)

Unknown

Isfahan University of Medical Sciences, Isfahan

All Listed Sponsors
lead

Isfahan University of Medical Sciences

OTHER

NCT05324995 - Peri-Articular-Multimodal Drug and Oral Celecoxib in Management of Postoperative Pain of Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter